Laureate Pharma Announces Agreement with Trubion Pharmaceuticals
12 February 2007
Princeton, NJ – Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced it has entered into an agreement to produce Trubion Pharmaceuticals, Inc.'s TRU-016, a novel protein for the treatment of Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Terms of the manufacturing agreement were not disclosed.
Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of NHL and CLL. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program.
"We are pleased that Trubion chose Laureate Pharma to manufacture TRU-016 for preclinical and clinical testing," noted Robert J. Broeze, PhD., President and Chief Executive Officer of Laureate Pharma, "and we look forward to working with them on this novel product."
